Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $86
Buy Rating on Structure Therapeutics: Promising GSBR-1290 Clinical Developments and Competitive Market Positioning
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy From Piper Sandler
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Structure Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and AbSci (ABSI)
Buy Rating Affirmed for Structure Therapeutics on Strong Pipeline and Undervalued Patent Portfolio
Deutsche Bank praises Eli Lilly and Co (LLY.US) as a "high-growth unicorn", with a target price skyrocketing to $1025.
Don't Forget This Startup's Weight-Loss Pill, Analyst Says -- Barrons.com
Structure Therapeutics Analyst Ratings
JMP Securities Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $86
Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $136
Buy Rating Affirmed: Undervalued Structure Therapeutics Poised for Growth With Strong R&D Pipeline and Strategic Partnerships